Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Aug 25, 2021

ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering

Aug 18, 2021

ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M

Aug 18, 2021

ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units

Aug 17, 2021

ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units

Aug 12, 2021

ProMIS Neurosciences Announces Second Quarter 2021 Results

Aug 4, 2021

ProMIS Neurosciences Issues Chairman’s Memorandum

Jul 22, 2021

ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference

Jul 8, 2021

ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus

Jul 2, 2021

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

Jun 8, 2021

ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease

  • arrow_back
  • 1…
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy